Bromide

Bromide

SCHEMBL17818451

Br.CNCCCNC(=O)OC(C)(C)C

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.62
MEN1 O00255 1/20 0.59
GAA P10253 1/20 0.59
KMT2A Q03164 1/20 0.59
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54
CA1 P00915 9/20 0.51
CA2 P00918 9/20 0.51
CA12 O43570 6/20 0.51
CA9 Q16790 6/20 0.51
STK17B O94768 1/20 0.46
STK17A Q9UEE5 1/20 0.46
EPHX1 P07099 1/20 0.44
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.40
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694362 0.98 TDP1 (0.65) TDP1MEN1GAAKMT2AMAOA
Hydrochloric Acid SCHEMBL30183864 0.96 TDP1 (0.62) TDP1MEN1GAAKMT2AMAOA
SCHEMBL691053 0.94 TDP1 (0.70) TDP1MEN1GAAKMT2AMAOA
SCHEMBL14571199 0.92 TDP1 (0.73) TDP1MEN1GAAKMT2AMAOA
SCHEMBL21996829 0.92 TDP1 (0.73) TDP1MEN1GAAKMT2AMAOA
SCHEMBL12772839 0.92 TDP1 (0.73) TDP1MEN1GAAKMT2AMAOA
SCHEMBL1588079 0.92 TDP1 (0.73) TDP1MEN1GAAKMT2AMAOA
SCHEMBL569251 0.90 TDP1 (0.74) TDP1MEN1GAAKMT2AMAOA
SCHEMBL7771476 0.86 TDP1 (0.56) TDP1MEN1GAAKMT2AMAOA
SCHEMBL46654 0.86 TDP1 (0.58) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3229593-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS Synereca Pharmaceuticals, Inc. (US) 2017-10-18 EP disclosed
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS (US) 2016-06-16 US disclosed
WO-2016094730-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS SYNERECA PHARMACEUTICALS, INC. (US) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168140-A1 HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS FOS, FOSB, YAP1 TDP1 3875/4885MEN1 751/4885GAA 2618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.